Scarica l'app Stockscreener
23.99
0.29%
0.07
Dopo l'orario di chiusura:
23.55
-0.44
-1.83%
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
Mineralys Therapeutics (MLYS) affiliate lists multi-date sales and a 3,542-share exercise - Stock Titan
Mineralys Therapeutics Reports Significant Reductions in Heart Failure Risk Biomarkers Associated with Lorundrostat in Proteomic Analysis - Quiver Quantitative
Blood protein shifts hint at heart failure pathways for lorundrostat - Stock Titan
Mineralys Therapeutics (MLYS) CMO sells 8,519 shares after option exercises - Stock Titan
Mineralys Therapeutics (NASDAQ: MLYS) files Rule 144 disclosing 6,349‑share cashless exercise - Stock Titan
Akin, an Elite Global Law Firm - Akin
Mineralys Therapeutics (MLYS) to Repurchase Potential Royalties for Lorundrostat - Insider Monkey
Transcript : Mineralys Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 02 - marketscreener.com
Mineralys Therapeutics Announces Royalty Repurchase, $500 Million Debt Facility, and $150 Million Equity Offering - Global Legal Chronicle
[144] Mineralys Therapeutics, Inc. SEC Filing - Stock Titan
5 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
MLYS: Lorundrostat advances toward launch with strong clinical data, strategic deals, and broad payer support - TradingView
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Biopharma Mineralys joins Goldman Sachs health-care talks in Miami - Stock Titan
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) - The Manila Times
Mineralys Therapeutics to Present Late-Breaking Data on - GlobeNewswire
Latham Advises Mineralys Therapeutics in Unique Three-Pronged Transaction — Royalty Repurchase, Debt Financing, and Equity Offering — Totaling Up to US$950 Million - Legal Desire Media and Insights
Mineralys Deepens Lorundrostat Bet With Royalty Buyout And New Data - Yahoo Finance
Mineralys Therapeutics Stock In Shambles: Down -25% With 6-Day Losing Streak - Trefis
Mineralys Therapeutics Stock Plummets 25% With 6-Day Losing Streak - Trefis
Precision Trading with Mineralys Therapeutics Inc. (MLYS) Risk Zones - Stock Traders Daily
Mineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical Efficacy - Insider Monkey
Mineralys Therapeutics prices $150M stock offering - MSN
Latham Advises Mineralys Therapeutics in Unique Three-Pronged - Latham & Watkins LLP
Mineralys pays up to $300 million to clear lorundrostat royalties - The Pharma Letter
MLYS Stock Sees 17.1% Decline Amid Market Movements - GuruFocus
Mineralys announces $150 million equity offering and financing - TipRanks
Mineralys (Nasdaq: MLYS) prices $150M stock sale to fund $200M royalty buyback - Stock Titan
Mineralys (MLYS) raises ~$150M in $26.50/share offering to fund royalty repurchase - Stock Titan
Mineralys Prices $150 Million Stock Offering, Repurchases Lorundrostat Royalty Obligations - Moomoo
Mineralys Stock Drops Before Open After $150 Million Sale Tests Blood-Pressure Drug Bet - Bez Kabli
Mineralys raises $750M through debt, equity and royalty deal By Investing.com - Investing.com India
Why Mineralys Therapeutics Stock Is Sliding Today - TipRanks
Mineralys prices $150 million stock offering at $26.50 per share By Investing.com - Investing.com South Africa
BioPharma Credit provides up to $150m loan to Mineralys By Investing.com - Investing.com Australia
BioPharma Credit provides up to $150m loan to Mineralys - Investing.com
Mineralys Secures Lorundrostat Rights and Major Financing Facility - TipRanks
Mineralys Therapeutics Files Form 8-K Announcing Material Definitive Agreement and Company Details - Minichart
Mineralys Therapeutics Announces Pricing Of $150 Million Underwritten Offering Of Common Stock - TradingView
Mineralys Therapeutics Announces Repurchase Of Royalty Obligations In Tanabe License Agreement And Concurrent Financing - TradingView
Mineralys prices $150 million stock offering at $26.50 per share - Investing.com UK
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock - The Manila Times
Mineralys raises $750M through debt, equity and royalty deal - Investing.com
Mineralys Locks In Royalty-Free Lorundrostat Rights With $200M Payment, Secures $500M Term Loan - TradingView
Mineralys Therapeutics Prices Underwritten Offering of 5.6 Million Shares at $26.50 Per Share, Expected to Raise $150 Million - Quiver Quantitative
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing - The Manila Times
Mineralys (NASDAQ: MLYS) gets $500M loan, ends lorundrostat royalty payments - Stock Titan
Mineralys Therapeutics, Inc. Enters into Senior Secured Term Loan Agreement for Up to $500 Million - marketscreener.com
Jefferies reiterates Hold on Mineralys stock amid M&A speculation By Investing.com - Investing.com Australia
Velan Capital Cuts Mineralys Therapeutics Stake by 140000 Shares - asatunews.co.id
Mineralys Therapeutics, Inc. (MLYS) Presents at 35th European Meeting on Hypertension and Cardiovascular ProtectionSlideshow (NASDAQ:MLYS) 2026-06-01 - Seeking Alpha
Jefferies reiterates Hold on Mineralys stock amid M&A speculation - Investing.com UK
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):